INNOVIVA, INC. Related Party Transaction, Revenues from Transactions with Related Party (Deprecated 2012-01-31)
INNOVIVA, INC. (INVA) reported Related Party Transaction, Revenues from Transactions with Related Party (Deprecated 2012-01-31) of $1.43 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-02.
Discontinued › Income Statement › Other Income
us-gaap:RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty · last filed 2012-05-02
- INNOVIVA, INC. related party transaction, revenues from transactions with related party (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $1.43M, a 41.78% decline year-over-year.
- INNOVIVA, INC. related party transaction, revenues from transactions with related party (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $2.36M, a 3.75% decline year-over-year.
- INNOVIVA, INC. related party transaction, revenues from transactions with related party (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $2.38M, a 3.09% decline year-over-year.
- INNOVIVA, INC. related party transaction, revenues from transactions with related party (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $2.46M, a 0.00% change year-over-year.
- INNOVIVA, INC. related party transaction, revenues from transactions with related party (deprecated 2012-01-31) for fiscal 2011 was $9.66M, a 1.71% decline from fiscal 2010.
- INNOVIVA, INC. related party transaction, revenues from transactions with related party (deprecated 2012-01-31) for fiscal 2010 was $9.83M, a 34.81% decline from fiscal 2009.
- INNOVIVA, INC. related party transaction, revenues from transactions with related party (deprecated 2012-01-31) for fiscal 2009 was $15.07M.
| Period end | Related Party Transaction, Revenues from Transactions with Related Party (Deprecated 2012-01-31) 3 month | Related Party Transaction, Revenues from Transactions with Related Party (Deprecated 2012-01-31) 6 month | Related Party Transaction, Revenues from Transactions with Related Party (Deprecated 2012-01-31) 9 month | Related Party Transaction, Revenues from Transactions with Related Party (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | $1.43M 10-Q · filed 2012-05-02 | $3.79M derived: sum of 2 quarters · filed 2012-05-02 | $6.17M derived: sum of 3 quarters · filed 2012-05-02 | $8.63M derived: sum of 4 quarters · filed 2012-05-02 |
| 2011-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27 | $4.74M derived: sum of 2 quarters · filed 2012-02-27 | $7.20M derived: sum of 3 quarters · filed 2012-02-27 | $9.66M 10-K · filed 2012-02-27 |
| 2011-09-30 | $2.38M 10-Q · filed 2011-11-02 | $4.84M derived: sum of 2 quarters · filed 2011-11-02 | $7.29M 10-Q · filed 2011-11-02 | $9.75M derived: sum of 4 quarters · filed 2012-05-02 |
| 2011-06-30 | $2.46M 10-Q · filed 2011-08-03 | $4.91M 10-Q · filed 2011-08-03 | $7.37M derived: sum of 3 quarters · filed 2012-05-02 | $9.82M derived: sum of 4 quarters · filed 2012-05-02 |
| 2011-03-31 | $2.46M 10-Q · filed 2012-05-02 | $4.91M derived: sum of 2 quarters · filed 2012-05-02 | $7.37M derived: sum of 3 quarters · filed 2012-05-02 | $9.82M derived: sum of 4 quarters · filed 2012-05-02 |
| 2010-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27 | $4.91M derived: sum of 2 quarters · filed 2012-02-27 | $7.37M derived: sum of 3 quarters · filed 2012-02-27 | $9.83M 10-K · filed 2012-02-27 |
| 2010-09-30 | $2.46M 10-Q · filed 2011-11-02 | $4.91M derived: sum of 2 quarters · filed 2011-11-02 | $7.37M 10-Q · filed 2011-11-02 | |
| 2010-06-30 | $2.46M 10-Q · filed 2011-08-03 | $4.91M 10-Q · filed 2011-08-03 | ||
| 2009-12-31 | $15.07M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |